Group-Based vs Individual Pelvic Floor Muscle Training to Treat Urinary Incontinence in Older Women: A Randomized Clinical Trial.


Journal

JAMA internal medicine
ISSN: 2168-6114
Titre abrégé: JAMA Intern Med
Pays: United States
ID NLM: 101589534

Informations de publication

Date de publication:
01 10 2020
Historique:
pubmed: 4 8 2020
medline: 17 4 2021
entrez: 4 8 2020
Statut: ppublish

Résumé

Urinary incontinence is one of the most prevalent health concerns experienced by older women (aged ≥60 years). Individual pelvic floor muscle training (PFMT) is the recommended first-line treatment for stress or mixed urinary incontinence in women, but human and financial resources limit its delivery. Whether group-based PFMT performs as well as individual PFMT in this population remains unclear. To assess the efficacy of group-based PFMT relative to individual PFMT for urinary incontinence in older women. The Group Rehabilitation or Individual Physiotherapy (GROUP) study is a single-blind, randomized, noninferiority trial conducted in 2 Canadian research centers, from July 1, 2012, to June 2, 2018. A total of 362 community-dwelling women aged 60 years or older with symptoms of stress or mixed urinary incontinence were enrolled. After an individual session conducted to learn how to contract pelvic floor muscles, participants completed 12-week PFMT as part of a group of 8 women (n = 178) or in individual sessions (n = 184). The primary outcome measure was the percentage reduction in urinary incontinence episodes at 1 year, as reported in a 7-day bladder diary and relative to pretreatment baseline. Secondary outcomes included lower urinary tract-related signs, symptoms, and quality of life immediately following treatment and at 1 year. Per-protocol analysis was used. Among 362 women who were randomized (mean [SD] age, 67.9 [5.8] years), 319 women (88%) completed the 1-year follow-up and were included in the per-protocol analysis. Median percentage reduction in urinary incontinence episodes was 70% (95% CI, 44%-89%) in individual PFMT compared with 74% (95% CI, 46%-86%) in group-based PFMT. The upper boundary of the 95% CI for the difference in the percentage reduction in urinary incontinence episodes at 1 year was lower than the prespecified margin for noninferiority of 10% (difference, 4%; 95% CI, -10% to 7%; P = .58), confirming noninferiority. Individual PFMT and group-based PFMT had similar effectiveness for all secondary outcomes at 1 year. Adverse events were minor and uncommon. Results of the GROUP study suggest that group-based PFMT is not inferior to the recommended individual PFMT for the treatment of stress and mixed urinary incontinence in older women. Widespread use in clinical practice may help increase continence-care affordability and treatment availability. ClinicalTrials.gov Identifier: NCT02039830.

Identifiants

pubmed: 32744599
pii: 2768776
doi: 10.1001/jamainternmed.2020.2993
pmc: PMC7400216
doi:

Banques de données

ClinicalTrials.gov
['NCT02039830']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1284-1293

Subventions

Organisme : CIHR
ID : MSH-258993
Pays : Canada
Organisme : CIHR
ID : PJT-148946
Pays : Canada

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Références

BJU Int. 2016 Jan;117(1):20-33
pubmed: 26033093
BMC Womens Health. 2009 Sep 14;9:26
pubmed: 19751517
Int Urogynecol J. 2017 Mar;28(3):351-359
pubmed: 27613622
Br J Obstet Gynaecol. 1997 Dec;104(12):1374-9
pubmed: 9422015
J Am Geriatr Soc. 2009 Mar;57(3):470-5
pubmed: 19187418
Int J Nurs Stud. 2011 Oct;48(10):1165-72
pubmed: 21459381
Neurourol Urodyn. 2015 Nov;34(8):747-51
pubmed: 25154378
Eur J Obstet Gynecol Reprod Biol. 2011 Dec;159(2):465-71
pubmed: 21962461
Int Urogynecol J Pelvic Floor Dysfunct. 2005 Jan-Feb;16(1):63-8; discussion 68
pubmed: 15647965
Neurourol Urodyn. 2011 Mar;30(3):317-24
pubmed: 21284022
J Am Geriatr Soc. 1991 Apr;39(4):378-82
pubmed: 2010587
J Clin Epidemiol. 2000 Nov;53(11):1150-7
pubmed: 11106889
Pharmacoepidemiol Drug Saf. 2013 Nov;22(11):1178-88
pubmed: 23939947
Neurourol Urodyn. 2010 Jun;29(5):727-34
pubmed: 19787711
Am J Manag Care. 2005 Jul;11(4 Suppl):S103-11
pubmed: 16161383
Cochrane Database Syst Rev. 2018 Oct 04;10:CD005654
pubmed: 30288727
JAMA. 2003 Jul 16;290(3):345-52
pubmed: 12865375
JAMA. 2002 Nov 13;288(18):2293-9
pubmed: 12425706
Neurourol Urodyn. 2010 Mar;29(3):344-7
pubmed: 19475576
Int Urogynecol J Pelvic Floor Dysfunct. 2009 Dec;20(12):1455-62
pubmed: 19690792
Trials. 2017 Nov 16;18(1):544
pubmed: 29145873
J Am Geriatr Soc. 1998 Jun;46(6):693-9
pubmed: 9625183
Neurourol Urodyn. 2018 Nov;37(8):2578-2585
pubmed: 30178571
BJU Int. 2001 Feb;87(3):201-6
pubmed: 11167642
J Am Geriatr Soc. 2003 Jul;51(7):979-84
pubmed: 12834518
Neurourol Urodyn. 2004;23(4):322-30
pubmed: 15227649
Gastroenterology. 2006 Apr;130(5):1480-91
pubmed: 16678561
JAMA. 2012 Dec 26;308(24):2594-604
pubmed: 23268518
Neurourol Urodyn. 2016 Feb;35(2):137-68
pubmed: 26749391
J Gerontol A Biol Sci Med Sci. 2001 Jan;56(1):M32-5
pubmed: 11193230
Adv Ther. 2006 Nov-Dec;23(6):999-1008
pubmed: 17276967
Am J Obstet Gynecol. 2003 Jul;189(1):98-101
pubmed: 12861145

Auteurs

Chantale Dumoulin (C)

School of Rehabilitation, Faculty of Medicine, Université de Montréal and Research Center of the Institut Universitaire de Gériatrie de Montréal, Montréal, Québec, Canada.

Mélanie Morin (M)

School of Rehabilitation, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Research Center of the Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Québec, Canada.

Coraline Danieli (C)

Research Institute of the McGill University Health Center, Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Québec, Canada.

Licia Cacciari (L)

School of Rehabilitation, Faculty of Medicine, Université de Montréal and Research Center of the Institut Universitaire de Gériatrie de Montréal, Montréal, Québec, Canada.

Marie-Hélène Mayrand (MH)

Department of Obstetrics and Gynecology and Social and Preventive Medicine, Université de Montréal, Research Center of the Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.

Michel Tousignant (M)

School of Rehabilitation, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Research Center of the Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Québec, Canada.

Michal Abrahamowicz (M)

Department of Epidemiology, Biostatistics, and Occupational Health, McGill University and Research Institute of the McGill University Health Center, Montreal, Québec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH